Welch & Forbes’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$88.3M Sell
167,666
-515
-0.3% -$289K 1.07% 25
2026
Q1
$94.5M Sell
168,181
-101
-0.1% -$64.8K 1.22% 23
2025
Q4
$114M Sell
168,282
-644
-0.4% -$439K 1.38% 20
2025
Q3
$108M Sell
168,926
-91
-0.1% -$55.2K 1.3% 21
2025
Q2
$90.7M Sell
169,017
-829
-0.5% -$396K 1.13% 30
2025
Q1
$71.3M Buy
169,846
+527
+0.3% +$229K 0.93% 35
2024
Q4
$70M Buy
169,319
+82
+0% +$36K 0.9% 37
2024
Q3
$85.5M Sell
169,237
-484
-0.3% -$235K 1.09% 29
2024
Q2
$81.2M Sell
169,721
-505
-0.3% -$254K 1.08% 28
2024
Q1
$91.9M Sell
170,226
-1,085
-0.6% -$593K 1.26% 23
2023
Q4
$95.1M Sell
171,311
-1,118
-0.6% -$525K 1.44% 19
2023
Q3
$75.4M Sell
172,429
-877
-0.5% -$437K 1.25% 23
2023
Q2
$87M Sell
173,306
-1,108
-0.6% -$531K 1.37% 20
2023
Q1
$87.2M Sell
174,414
-1,843
-1% -$882K 1.48% 19
2022
Q4
$71.9M Sell
176,257
-2,274
-1% -$883K 1.29% 22
2022
Q3
$58.2M Sell
178,531
-471
-0.3% -$173K 1.14% 27
2022
Q2
$62.8M Buy
179,002
+199
+0.1% +$81.1K 1.15% 28
2022
Q1
$97.8M Buy
178,803
+4,311
+2% +$2.27M 1.54% 17
2021
Q4
$115M Sell
174,492
-817
-0.5% -$513K 1.72% 15
2021
Q3
$109M Sell
175,309
-1,943
-1% -$1.31M 1.81% 15
2021
Q2
$112M Sell
177,252
-506
-0.3% -$279K 1.89% 14
2021
Q1
$87M Sell
177,758
-1,928
-1% -$966K 1.61% 16
2020
Q4
$89.8M Sell
179,686
-1,376
-0.8% -$616K 1.76% 14
2020
Q3
$71.2M Sell
181,062
-1,606
-0.9% -$594K 1.54% 17
2020
Q2
$60.3M Buy
182,668
+1,469
+0.8% +$425K 1.41% 20
2020
Q1
$43.9M Buy
181,199
+492
+0.3% +$128K 1.23% 23
2019
Q4
$47.2M Sell
180,707
-1,038
-0.6% -$274K 1.05% 23
2019
Q3
$49.4M Buy
181,745
+1,134
+0.6% +$316K 1.18% 23
2019
Q2
$49.7M Buy
180,611
+9,419
+6% +$2.32M 1.21% 23
2019
Q1
$38.3M Sell
171,192
-8,383
-5% -$1.73M 0.96% 33
2018
Q4
$33.4M Sell
179,575
-1,547
-0.9% -$317K 0.94% 37
2018
Q3
$45.2M Sell
181,122
-3,458
-2% -$839K 1.08% 26
2018
Q2
$40.2M Sell
184,580
-1,778
-1% -$366K 1.04% 31
2018
Q1
$35.7M Sell
186,358
-2,654
-1% -$490K 0.92% 37
2017
Q4
$29.6M Sell
189,012
-3,984
-2% -$627K 0.79% 40
2017
Q3
$30M Sell
192,996
-1,403
-0.7% -$222K 0.79% 44
2017
Q2
$31.4M Buy
194,399
+3,701
+2% +$601K 0.88% 36
2017
Q1
$29.5M Sell
190,698
-4,546
-2% -$627K 0.84% 37
2016
Q4
$22.9M Buy
195,244
+80
+0% +$9.13K 0.69% 53
2016
Q3
$22M Sell
195,164
-3,026
-2% -$319K 0.76% 44
2016
Q2
$18.4M Buy
198,190
+1,169
+0.6% +$100K 0.56% 63
2016
Q1
$15.4M Sell
197,021
-2,622
-1% -$189K 0.48% 71
2015
Q4
$14.6M Buy
199,643
+1,230
+0.6% +$87.7K 0.47% 71
2015
Q3
$14.7M Sell
198,413
-2,950
-1% -$211K 0.49% 67
2015
Q2
$12.9M Buy
201,363
+95
+0% +$6.58K 0.4% 75
2015
Q1
$15.5M Sell
201,268
-7,286
-3% -$567K 0.47% 71
2014
Q4
$15.5M Sell
208,554
-3,470
-2% -$243K 0.45% 73
2014
Q3
$12.5M Sell
212,024
-2,102
-1% -$133K 0.38% 77
2014
Q2
$14.3M Sell
214,126
-10,734
-5% -$683K 0.45% 70
2014
Q1
$13.6M Sell
224,860
-10,148
-4% -$605K 0.43% 74
2013
Q4
$12.5M Sell
235,008
-13,142
-5% -$692K 0.4% 79
2013
Q3
$12.4M Sell
248,150
-6,000
-2% -$288K 0.42% 77
2013
Q2
$11.4M Buy
+254,150
New +$11.1M 0.41% 74

Other funds holding IDXX

Welch & Forbes's IDXX Position: Q2 2026 in Review

Welch & Forbes reduced its Idexx Laboratories (IDXX) stake by 0.31% in Q2 2026, selling an estimated $289K and leaving 167,666 shares worth $88.3M. The position accounts for 1.07% of the portfolio, ranked #25.

Welch & Forbes first reported a position in IDXX in Q2 2013 and has held it in 53 quarters since. The position peaked at $115M in Q4 2021. 1,300 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Welch & Forbes held 167,666 shares of Idexx Laboratories worth $88.3M as of Q2 2026.
  • Welch & Forbes sold 515 Idexx Laboratories shares in Q2 2026, an estimated $289K.
  • Idexx Laboratories made up 1.07% of Welch & Forbes's portfolio in Q2 2026, its #25 holding.
  • Welch & Forbes first reported a position in Idexx Laboratories in Q2 2013 and has held it in 53 quarters since.
  • Welch & Forbes's Idexx Laboratories position peaked at $115M in Q4 2021.
  • 1,300 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Welch & Forbes's 13F filing for Q2 2026, filed 30 Jul 2026.